The Laboratory Case: Credible Mechanisms
Tea polyphenols, particularly EGCG, interfere with cancer cell biology through multiple mechanisms: (1) Cell cycle arrest — inhibiting cyclin D1 and CDK4, preventing G1→S phase transition; (2) Apoptosis induction — activating caspase cascades via the mitochondrial pathway; (3) Angiogenesis inhibition — blocking VEGF signalling, preventing new blood vessel formation to supply tumours; (4) Invasion inhibition — downregulating MMP-9 and MMP-2, preventing extracellular matrix degradation; (5) Epigenetic effects — DNMT and HDAC inhibition reactivating silenced tumour suppressor genes (see our epigenetics guide).
🧠 Expert Tip: Mechanistic vs Clinical
Understanding a mechanism does not confirm clinical efficacy. Many compounds with compelling anti-cancer mechanisms in cell culture have failed in clinical trials. The history of cancer drug development is littered with promising laboratory results that did not translate to human benefit. Tea polyphenols may ultimately prove more useful as prevention adjuncts than as treatments — and at much lower doses than early laboratory work suggested.
Human Epidemiology: What Population Studies Show
The most consistently positive associations are found for: (1) Stomach cancer — multiple large cohort studies in Japan and China find 20–40% lower risk in high versus low green tea consumers; (2) Oesophageal cancer — consistent inverse associations in Chinese populations (though very hot tea independently increases oesophageal cancer risk via thermal injury, an important confound); (3) Liver cancer — Japanese cohort studies find approximately 30% lower risk in daily green tea consumers.
Associations with breast, colorectal, and prostate cancer are much less consistent — some studies show modest inverse associations, others null results, and occasional positive associations (dependent on study design, population, and adjustment for confounders like smoking and diet).
Clinical Trials: The Honest Picture
Randomised controlled trials of green tea extracts for cancer prevention or treatment are limited in number, generally small, and show inconsistent results. The most positive: a 2008 Italian trial found that green tea extract (600mg EGCG daily) significantly reduced the progression of high-grade prostate intraepithelial neoplasia (HGPIN, a cancer precursor) to prostate cancer over 12 months. The most sobering: multiple trials in already-established cancers found no meaningful clinical benefit, consistent with the hypothesis that EGCG effects are most relevant at the prevention/initiation stage.
Comments